Cannabis Europa London returns to the iconic Barbican Centre on May 26-27, 2026, bringing together Europe’s most influential policymakers, investors, and medical cannabis executives under one roof. As the continent’s flagship policy-focused cannabis conference, this event offers cultivators and processors direct access to the decision-makers shaping UK and European regulatory frameworks.
The UK medical cannabis market has undergone remarkable transformation, with prescription volumes increasing 130% between 2022/23 and 2023/24. With the patient population projected to reach 80,000 by end of 2025, Cannabis Europa provides unmatched networking opportunities for international producers seeking UK market entry.
The UK medical cannabis market grew 262% in prescription volume over two years, with over 99% of prescriptions coming through private clinics.
Whether you’re evaluating EU-GMP certification pathways, seeking Home Office import licence guidance, or building relationships with UK private clinic networks, Cannabis Europa London brings together the MHRA officials, regulatory consultants, and industry leaders you need to meet.
Cannabis Europa’s policy-forward agenda attracts decision-makers across the cannabis supply chain who are evaluating UK market entry or seeking to build commercial partnerships in Britain’s growing medical cannabis sector.
The UK medical cannabis market has undergone significant transformation. Prescription volumes increased 130% between 2022/23 and 2023/24, jumping from 150,527 to 346,600 items dispensed. The new Labour government, elected in 2024, has maintained existing medical cannabis access while the May 2025 London Drugs Commission report called for decriminalisation – signaling potential future policy shifts.
Cannabis Europa has expanded to Paris alongside London, establishing a true pan-European platform. The 2026 London edition returns to the Barbican Centre – where the conference originated in 2018 – with an enhanced focus on UK-EU regulatory alignment post-Brexit. The conference positions itself uniquely at the intersection of policy and commerce, putting policymakers, regulators, and investors at the same table as industry leaders.
UK imports increased 394% in 2024 to reach 326 kg, with early 2025 volumes already exceeding 1 tonne as distribution infrastructure scales rapidly.
Cannabis Trades Association UK, 2025Whether you’re attending for the first time or returning to expand your network, these practical tips will help you maximize your conference experience.
The UK operates a unique dual-track system where over 99% of prescriptions come through 40+ CQC-registered private clinics rather than the NHS. Only GMC Specialist Register doctors can prescribe unlicensed CBPMs. This private clinic model creates distinct market dynamics for international cultivators seeking UK partnerships.
Related: Understanding UK MHRA Requirements for Cannabis OperationsCannabis businesses expanding into the UK market encounter operational complexities that require significant planning and system adaptation. Conference attendees frequently discuss these common challenges:
Navigating the Controlled Drug licence application process and maintaining ongoing compliance with import/export requirements
Building robust quality assurance systems that satisfy MHRA auditors and maintain continuous compliance for pharmaceutical-grade products
Establishing distribution partnerships with the 40+ private clinics that represent over 99% of UK patient access
Managing compliance across UK and EU jurisdictions simultaneously as regulatory frameworks continue to diverge
Maximize your conference ROI by arriving prepared. Use this checklist to ensure you’re ready to make the most of every networking opportunity and business meeting.
Common questions from cannabis professionals planning to attend Cannabis Europa London 2026.
Cannabis Europa is predominantly B2B, with 90% of attendees representing businesses, investors, and policy professionals. The policy focus means less consumer-facing content compared to events like Mary Jane Berlin.
Yes. Cannabis Europa welcomes international delegates and specifically targets a pan-European and global audience. The conference language is English. International cultivators seeking UK market entry form a significant attendee segment.
The Business of Cannabis Awards is a prestigious evening ceremony on May 26, recognising excellence across the European cannabis industry. Access is included with VIP+ ticket purchases (GBP 840).
Yes. Beyond organic networking during breaks, Cannabis Europa offers VIP lounge access, Awards ceremony evening networking, and structured meeting scheduling for sponsors and exhibitors.
Super Early Bird Pass (GBP 334.49), VIP Pass (GBP 756.59) with lounge and lunch, and VIP + Awards (GBP 840) including the evening ceremony. Registration is via Eventbrite.
Cannabis Europa’s 95% medical focus means strong representation from pharmaceutical companies, private clinics, EU-GMP certified cultivators, investors, regulatory professionals, and government representatives.
Cannabis operations expanding into the UK market increasingly rely on seed-to-sale platforms capable of generating MHRA-compliant documentation and managing cross-border regulatory reporting. These systems help operators maintain audit-ready records across cultivation, processing, and distribution activities.
Attendees at Cannabis Europa often evaluate technology solutions that can adapt to UK-specific requirements while maintaining consistent operational workflows across multiple facilities and jurisdictions. With the UK’s unique private clinic model, robust batch traceability and quality documentation are essential.
See how cannabis facilities in the UK use GrowerIQ to manage seed-to-sale traceability and MHRA-compliant documentation.
Request Demo